At the last check on Friday, Horizon Therapeutics Public Limited Company’s (NASDAQ:HZNP) stock was up $1.42, moving up 1.43 percent to $100.40. The average number of shares traded per day over the past five days has been 1,355,135 shares. 2 times new highs have been achieved over the past 5 days, with a $0.39 gain in that time frame. In the last twenty days, the average volume was 1,674,239, while in the previous 50 days, it was 1,614,003.
Since last month, HZNP stock retreated -2.24%. Shares of the company fell to $98.80 on 08/03/23, the lowest level in the past month. A 52-week high of $113.83 was reached on 01/03/23 after having rallying from a 52-week low of $57.84. Since the beginning of this year, HZNP’s stock price has dropped by -11.78% or -$13.47, and marked a new high 1 time. However, the stock has declined by -11.80% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
HZNP stock investors should be aware that Horizon Therapeutics Public Limited Company (HZNP) stock had its last reported insider trading activity 199 days ago on Jan 17. Pasternak Andy, the EVP, Chief Strategy Officer of the company, disposed of 27,129 shares for $113.03 on Jan 17. It resulted in a $3,066,323 divestment by the insider. Cox Aaron sold 36,148 shares at an average price of $113.17 on Jan 13. The insider now owns 277 shares following the transaction. On Jan 11, EVP and Chief Medical Officer SHERMAN JEFFREY W sold 3,368 shares at $113.10 apiece. The transaction was valued at $380,921.
Valuation Metrics
Right now, Horizon Therapeutics Public Limited Company (HZNP) has a P/E ratio of about 63.30. The stock’s beta is 1.06. Besides these, the trailing price-to-sales (P/S) ratio of 6.41, the price-to-book (PB) ratio of 4.50, and the price-to-cash flow ratio of 21.72 may also be considered.
Financial Health
In the three months ended March 30, Horizon Therapeutics Public Limited Company’s quick ratio stood at 3.90, while its current ratio was 4.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.50, and the total debt-to-equity ratio was 0.50. On the profitability front, the trailing twelve-month gross margin is 74.40% percent. In the year ended March 30, EBITDA margin amounted to 30.09%, whereas operating margins totaled 12.80%. Based on annual data, HZNP earned $2.71 billion in gross profit and brought in $3.63 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 8.00%. Return on equity (ROE) for the past 12 months was 7.40%.
In Horizon Therapeutics Public Limited Company’s quarter-end financial report for March 30, it reported total debt of $2.54 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. HZNP’s revenue fell -6.39% to $942.03 million during the quarter, while net income inched up to $832.06 million. While analysts expected Horizon Therapeutics Public Limited Company to report $1.12 quarterly earnings, the actual figure was $0.83 per share, beating the consensus estimate by -25.90%. During the quarter, the company generated $132.32 million in EBITDA. The liabilities of Horizon Therapeutics Public Limited Company were 3.9 billion at the end of its most recent quarter ended March 30, and its total debt was $2.68 billion. The value of shareholders’ equity is $228.62 million.
Technical Picture
This quick technical analysis looks at Horizon Therapeutics Public Limited Company’s (HZNP) price momentum. With a historical volatility rate of 9.31%, the RSI 9-day stood at 45.38% on 03 August.
With respect to its five-day moving average, the current Horizon Therapeutics Public Limited Company price is up by +0.39% percent or $0.39. At present, HZNP shares trade -2.31% below its 20-day simple moving average and -8.33% percent below its 100-day simple moving average. However, the stock is currently trading approximately +0.23% above its SMA50 and +56.25% above its SMA200.
Stochastic coefficient K was 10.55% and Stochastic coefficient D was 7.62%, while ATR was 0.99. Given the Stochastic reading of 27.62% for the 14-day period, the RSI (14) reading has been calculated as 43.03%. As of today, the MACD Oscillator reading stands at -0.33, while the 14-day reading stands at -1.24.
Analyst Ratings
H.C. Wainwright launched its rating on Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) to a Neutral in a note to investors on November 01, 2022. Horizon Therapeutics Public Limited Company (HZNP) has been rated Hold by analysts. According to 0 brokerage firms, HZNP is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Horizon Therapeutics Public Limited Company stock as buy, with 1 recommending it as overweight.
With a median target price of $116.50, the current consensus forecast for the stock is $116.50 – $116.50. Based on these forecasts, analysts predict Horizon Therapeutics Public Limited Company (HZNP) will achieve an average price target of $116.50.
